RiverVest Venture Partners focuses on early-stage life science companies, leveraging extensive operating expertise to shape and create significant shareholder value. The firm primarily invests in Series A and B rounds, with a strong presence in Series C and later stages. RiverVest's investment strategy centers on identifying promising opportunities in the biotechnology and medical device sectors.
Notable portfolio companies include Mirum Pharmaceuticals, Wugen, and Spruce Biosciences. RiverVest's approach combines scientific insight, strategic guidance, and innovative thinking to support entrepreneurs in improving patients' lives. The firm offers value-add services to portfolio companies, utilizing its deep industry knowledge and connections to help startups navigate the complex life sciences landscape.
RiverVest - Portfolio Snapshot
Portfolio activity breakdown across disclosed investments and stages
Portfolio Companies25
Follow-on Investments16
Current Portfolio Count24
Top Investment Stages
Series A14 (40.0%)
Series B14 (40.0%)
Series C5 (14.3%)
Series D2 (5.7%)
Stage Mix
Series A 40%Series B 40%Series C 14%Series D 6%
Concentration shown as share of disclosed investments by stage.
RiverVest - Classification
- NAICS
- 520000Finance and Insurance
- 523000Securities, Commodity Contracts, and Other Financial Investments and Related Activities
- 523900Other Financial Investment Activities
- 523990All Other Financial Investment Activities
- 523999Miscellaneous Financial Investment Activities
- SIC
- 6700Holding And Other Investment Offices
- 6790Miscellaneous Investing
- 6799Investors, Not Elsewhere Classified
Show 6 more industry codes
- NAICS
- 525000Funds, Trusts, and Other Financial Vehicles
- 523910Miscellaneous Intermediation
- 523940Portfolio Management and Investment Advice
- SIC
- 6000Depository Institutions
- 6720Investment Offices
- 6722Management Investment Offices, Open-end
